FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: *Pivot Pharmaceuticals Inc. (the “Issuer”)*

Trading Symbol: *PVOT*

Number of Outstanding Listed Securities: *96,578,249 common shares*

Date: *November 5, 2018*

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*During October 2018, Pivot continued to position itself to maximize value to its shareholders. Pivot signed letter of intent for the reverse takeover of Knol Resources Corp. (“Knol”), a company listed on the TSX-V, pursuant to which Pivot will spin out non-U.S. cannabis assets to Knol.*

*Pivot signed a letter of intent to create a Joint Venture with Cartagena Inc. ("the Cartagena Joint Venture"), a subsidiary of Mexico-based Licorera Del Sur. The Cartagena Joint Venture will develop and commercialize cannabis-infused non-alcoholic beverages using Pivot's patented, water-soluble powdered cannabis technologies combined with Cartagena's fine spirits and flavoured extract formulations.*

*In addition, Pivot signed a letter of letter of intent to create a joint venture with Mexico-based Intercontinental Marketing Co., S.A. de C.V. (“IMACO”) for the purposes of importing, registering and distributing Pivot’s patented line of bio-cannabis products into the Mexican market.*

*In October 2018, Pivot’s wholly-owned subsidiary, Pivot Naturals LLC, signed a Contract Manufacturing and Licensing Agreement with Ananda Acquisitions LLC, whereby Pivot will formulate and manufacture various cannabis-infused edible products for Ananda using Pivot's patented Ready-To-Infuse-Cannabis ("RTIC") technology. Pursuant to the agreement, Pivot received an initial formulation fee of USD $120,000.*

*On the financing front, Pivot closed a non-brokered private placement for a total of $1,641,300 and settled $1,500,000 of outstanding debt with the issuance of common shares and share purchase warrants.*

1. Provide a general overview and discussion of the activities of management.

*Please see Item 1.*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*None.*

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*None.*

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*Please see Item 1.*

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*None.*

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*None.*

1. Describe the acquisition of new customers or loss of customers.

*Not applicable.*

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

*None.*

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*None.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

*Not applicable.*

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*None.*

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*Pursuant to the settlement $1,500,000 of outstanding debt with the issuance of common shares and share purchase warrant, Pivot issued 3,750,000 units consisting of one common share and one share purchase warrant, expiring in three years and entitling the holder to purchase one common share for each share purchase warrant at an exercise price of $0.60.*

1. Provide details of any securities issued and options or warrants granted.

*Pursuant to the non-brokered private placement for a total of $1,641,300, Pivot issued 4,078,250 units consisting of one common share and one share purchase warrant, expiring in three years and entitling the holder to purchase one common share for each share purchase warrant at an exercise price of $0.60. Agent fees consisted of $88,104 in cash and 220,260 agent warrants, expiring in three years and entitling the agent to purchase one common share for each agent warrant at an exercise price of $0.60.*

1. Provide details of any loans to or by Related Persons.

*None.*

1. Provide details of any changes in directors, officers or committee members.

*None.*

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

*None.*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 5, 2018

 Moira Ong
Name of Director or Senior Officer

 *“Moira Ong”*
Signature

Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerPivot Pharmaceuticals Inc. | For Month EndOctober 2018 | Date of ReportYY/MM/D2018/11/5 |
| Issuer Address1275 West 6th Avenue, Suite 300 |
| City/Province/Postal CodeVancouver, BC V6H 1A5 | Issuer Fax No.( ) | Issuer Telephone No.( ) |
| Contact NamePatrick Frankham | Contact PositionCEO | Contact Telephone No.514-943-1899 |
| Contact Email Addressinfo@pivotpharma.com | Web Site Addresswww.pivotpharma.com |